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Abstract
Introduction: TRAIL protein may serve as an escape mechanism for cancer cells
from the immune response. The aim of the study was to assess whether the
presence of TRAIL protein correlates with unfavourable prognostic factors in
breast carcinoma. 
Material and methods: The study group was composed of breast cancer patients
treated surgically in the Department of Surgical Oncology, Medical University
of Lodz, Poland, from January to December 2003. Inclusion criteria for the study
were fulfilled by 117 women. The immunohistochemical study of TRAIL protein
expression was performed in 118 breast carcinomas diagnosed in the study
group. TRAIL protein expression was correlated with other variables: tumour
size, lymph node status, grade, histological type of carcinoma, oestrogen and
progesterone receptor status, HER2 expression, presence of lymphovascular
invasion and age of the patient.
Results: Expression of TRAIL protein was present in 73% of breast carcinomas.
The percentage of TRAIL-expressing breast carcinoma cells correlated with the
nuclear grade (τ = 0.26, p < 0.05; Tau Kendall test). The intensity of TRAIL
expression (intensity of staining) in breast carcinoma cells correlated with the
nuclear grade (τ = 0.15, p < 0.05; Tau Kendall test). TRAIL expression in breast
carcinoma did not correlate with other studied variables.
Conclusions: Our analysis revealed that expression of TRAIL protein in breast
carcinoma cells correlates with nuclear grade of carcinoma.
Key words: apoptosis, expression, immunohistochemistry.
Introduction
Apoptosis is a crucial mechanism of homeostasis in complex biological
systems [1]. Three types of elements play an essential part in this process:
activators, inhibitors, and effectors. The TRAIL protein, discovered in 1995
to be one of a family of tumour necrosis factors (TNF), acts as an activator
of apoptosis [2]. The TRAIL ligand interacts with 5 receptors. Two of them,
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death receptor-4 (DR4) and death receptor-5 (DR5),
act agonistically; they activate apoptosis [3, 4]. The
remaining 3 receptors, decoy receptor 1 (DcR1),
decoy receptor 2 (DcR2) and osteoprotegerin, act
antagonistically [5-7]. It was suggested that the
TRAIL protein may have potent anticancer activity
toward normal tissue without significant toxicity
[8, 9], making it a potential anticancer drug. It was
shown that TRAIL induces apoptosis in a variety of
transformed cell lines. It has also been shown in an
experimental study that the use of recombinant
TRAIL protein is safe [10, 11]. 
The expression of TRAIL protein has been
discovered in numerous normal cells and tissues in
the human body. The expression of TRAIL has been
found in cells of normal liver, kidneys, heart, colon,
lungs, testes [12], and in immunological system cells
[13]. In cancer cells, TRAIL protein expression may
be higher or lower than in normal cells [14-17].
Nevertheless, the physiological role of the TRAIL
protein in cancer cells is still not clear. 
It has been suggested that expression of TRAIL
protein may be a part of the escape mechanism for
cancer cells from the immune response. TRAIL may
induce apoptosis of activated lymphocytes [18],
including tumour-infiltrating lymphocytes (TIL) [19].
Moreover, it has been demonstrated that the
intensity of apoptosis correlates with the expression
of another ligand from the TNF family, FasL, which
is functionally similar to TRAIL [20-22]. In this
aspect, the presence of TRAIL in cancer cells should
be unfavourable for the patient as the decrease in
number and decrease in cytotoxic activity of TIL
deteriorate the prognosis [23]. 
On the other hand, expression of TRAIL protein
in cancer cells may inhibit tumour growth by
autocrine or paracrine induction of cancer cell
apoptosis [24-26]. Moreover, induction of TRAIL
expression may substantially increase paracrine-
led cancer cell apoptosis, without an increase of
normal cell apoptosis [27]. The results of studies
are not unanimous. Some of them show a lack of
correlation between TRAIL expression and the
intensity of cancer cell apoptosis [15, 28]. For all
these reasons, it is very difficult to define the real
role of TRAIL in cancer cells. 
Assuming that the expression of TRAIL protein
serves as an escape mechanism for cancer cells from
the immune response, it can be expected that TRAIL
should be an unfavourable prognostic factor. It
would be interesting to assess whether the presence
of TRAIL protein correlates with other unfavourable
prognostic factors. It was therefore decided to
search for such correlations in breast cancers. 
Material and methods
The study group was composed of breast cancer
patients treated surgically in the Department of
Surgical Oncology, Medical University of Lodz,
Poland, from January to December 2003. The of
each patient were examined for details of physical
findings, type of surgery and results of pathological
examination. Inclusion criteria for the present study
were as follows: (1) axillary lymphadenectomy was
performed during surgical treatment, as part of
modified radical mastectomy or conservative
surgery, (2) breast carcinoma was invasive, and 
(3) no neoadjuvant treatment was used. Moreover,
all patients with metaplastic breast carcinoma were
excluded. Complete clinical and pathological data,
together with samples of archival breast cancer
tissue, were obtained from 117 patients. As one of
the breast carcinoma patients had bilateral breast
carcinoma, the study was performed on 118 breast
carcinoma cases. In order to examine the
relationship between TRAIL expression and other
clinical and pathological variables, an immuno  -
histochemical study of TRAIL expression was
performed. Immunohistochemical assessment of
ER and PR expression, as well as assessment 
of HER2 expression in breast carcinomas, was
carried out as part of a routine postoperative
pathological workup. The results were the source
for statistical calculations. 
The study was approved by the ethical
committee of the Medical University of Lodz
(RNN/19/08/KE). 
Immunohistochemical stainings for TRAIL, ER,
PR and HER2
For immunohistochemical staining, 4-µm-thick
sections cut from formalin-fixed, paraffin-embedded
tissue were used. After deparaffinization in xylene
and hydration in graded ethanol solutions, the
sections of breast carcinoma tissue for TRAIL, ER
and PR staining were subjected to pre-treatment
in a microwave oven in citrate buffer, in order to
enhance antigen retrieval. The EnVision+ System-
HRP (DAB) (DakoCytomation) was used for the
detection of immunostainings performed with
primary antibodies against TRAIL antigen (Novo  -
castra), ER and PR (Dako, Glostrup, Denmark). The
immunostainings were performed according to the
protocol described by the manufacturer. The
dilutions of primary antibodies against TRAIL,
against ER and against PR were 1 : 50. All
incubations with the primary antibodies were
conducted at 20-25°C. Those for TRAIL lasted 
30 min while those for ER and PR lasted 60 min. As
a final step, counterstaining with haematoxylin was
performed. Positive controls (antigen-positive
tissue) for the immunostaining technique were
used. The immunostaining for HER2 was performed
with the use of HercepTest® (Dako, Glostrup,
Denmark) strictly according to the protocol
described by the manufacturer. All immunostainingsArch Med Sci 4, August / 2010 547
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were performed in the Department of Pathology,
Chair of Oncology, Medical University of Lodz. 
Evaluation of TRAIL expression
Two variants of evaluation of immunohis  to  -
chemistry results were used. In the first, “simple”
variant, TRAIL expression was classified as
a binominal variable. The absence of TRAIL
expression was defined as the absence of stained
cells or presence of cytoplasmic staining in less than
10% of carcinoma cells. The presence of staining in
at least 10% of carcinoma cells was considered as
evidence of TRAIL expression.  
In the second variant of evaluation, the
percentage of stained cells and intensity of staining
were classified separately. The percentage of
stained cells was graded from 0 to 3 (0 = less than
10% of cells stained, 1 = 10-39%, 2 = 40-69%, 3 =
at least 70% of cells stained). Intensity of staining
was graded from 0 to 3 (0 = lack of staining or very
weak intensity of staining; 1 = weak intensity of
staining; 2 = moderate intensity of staining; 3 =
strong intensity of staining). 
Evaluation of ER and PR expression
The scoring of ER and PR nuclear reactivity was
done using the method described by McCarty et al.
[29]. Both the percentage of stained cells and the
intensity of reaction were taken into account. Histo-
score (HS) was calculated for each carcinoma using
the mathematical formula:
HS = x(+) + 2x(++) + 3x(+++),
where:
x(+) was the percentage of cells with weak intensity
of staining,
x(++) was the percentage of cells with moderate
intensity of staining,
x(+++) was the percentage of cells with strong
intensity of staining.
The expression of oestrogen receptor and
expression of progesterone receptor were graded in
relation to histo-score value: histo-score 0-100 = (0)
absence of expression, histo-score 101-200 = (1+)
weak expression, histo-score 201-300 = (2+)
moderate expression, histo-score 301-400 = (3+)
strong expression.
Evaluation of HER2 staining
The scoring system recommended by the
manufacturer of the HercepTest (Dako, Glostrup,
Denmark) was used for the evaluation of HER2
staining. HER2 was scored 0 when no staining was
observed or membrane staining was observed in
less than 10% of the carcinoma cells. It was scored
1+ when faint/barely perceptible membrane staining
was detected in more than 10% of carcinoma cells,
but cells exhibited incomplete membrane staining.
It was scored 2+ when weak to moderate complete
membrane staining was observed in more than 10%
of carcinoma cells. It was scored 3+ when strong
complete membrane staining was observed in more
than 10% of carcinoma cells.  
Statistical analysis
Statistical analysis was performed using
STATISTICA 8.0 statistical package (StatSoft, Tulsa,
USA). Two-tailed, exact Fisher’s test or Yates
corrected χ2 test was used depending on the
number of observations. The normality of the
distribution of continuous variables was verified
using Shapiro-Wilk W test. In cases of non-normally
distributed values, logarithmic transformation was
attempted. Nonparametric tests were used if the
distribution remained non-normal. Correlation
computations were performed using the Spearman
R and Tau Kendall tests. In all cases, the threshold
of statistical significance was the probability of
a type I error lower than 0.05.
Results
Patients
In the study group, 118 breast carcinomas were
diagnosed in 117 women. The median age of
patients at the time of diagnosis of breast
carcinoma was 56 years (range, 26-81 years). Breast
carcinomas were located in the left breast in 57
cases (48.3%) and in the right breast in 61 cases
(51.7%).
Breast carcinomas
Invasive ductal carcinoma was the dominant
type of cancer. It was diagnosed in 90 cases (90/118,
76.3%). In 21 cases invasive lobular carcinoma was
diagnosed (21/118, 17.8%). Among the remaining 
7 carcinomas (7/118, 5.9%), histological types were
as follows: invasive ductal-lobular (3 cases),
medullary (2 cases), mucinous (1 case), and alveolar
(1 case) (WHO 2004 histological classification). The
nuclear grade was classified as G3 in 54 carcinomas,
as G2 in 50 carcinomas and as G1 in 14 carcinomas.
The median size of the primary tumours was
2.25 cm (range 0.5-8 cm, mean 2.4 cm, standard
deviation 1.32 cm). Metastases in axillary lymph
nodes were found in 59 cases (59/118, 50.0%). In
the remaining 59 cases, no metastases were found
(59/118, 50.0%). In 33 cases, metastases in lymph
nodes infiltrated the lymph node capsule (33/118,
28.0%). Lymphovascular invasion was found in 
17 cases (17/118, 14.4%). In the whole group of 118
primary carcinomas, 33 were classified as stage I
carcinomas (33/118, 28.0%), 41 as IIA carcinomas
(41/118, 34.8%), 43 as IIB carcinomas (43/118,
36.4%) and one as IIIA carcinoma (1/118, 0.8%).548 Arch Med Sci 4, August / 2010
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Expression of TRAIL in breast carcinoma  Number of cases Percentage of cases 
Percentage of stained cells 
Less than 10% of cells (grade 0) 32/118 27.1
10-39% of cells (grade 1+) 13/118 11.0
40-69% of cells (grade 2+) 26/118 22.0
At least 70% of cells (grade 3+) 47/118 39.8
Intensity of staining
Absence of staining (grade 0) 32/118 27.1
Weak intensity of staining (grade 1+) 24/118 20.3
Moderate intensity of staining (grade 2+) 43/118 36.4
Strong intensity of staining (grade 3+) 19/118 16.1
Table I. Results of immunohistochemical study of TRAIL expression in 118 primary breast carcinomas
Results of immunohistochemical stainings 
for TRAIL, ER, PR and HER2
In 32 primary breast carcinomas, TRAIL expres  -
sion was absent (32/118, 27.1%) (Figure 1). In the
remaining 86 of 118 primary breast carcinomas, the
expression of TRAIL was present (86/118, 72.9%)
(Figure 2). The results of immunohistochemical
staining for TRAIL are presented in detail in Table I.
The results of immunohistochemical stainings for
ER, PR and HER2 are presented in detail in Table II. 
Correlations of TRAIL expression
The percentage of TRAIL-expressing breast
carcinoma cells correlated with the nuclear grade
(τ = 0.26, p < 0.05; Tau Kendall test). Also the
intensity of TRAIL expression (intensity of staining)
in breast carcinoma cells correlated with the nuclear
grade (τ = 0.15, p < 0.05; Tau Kendall test).
The percentage of TRAIL-expressing breast
carcinoma cells did not correlate with the diameter
of the primary tumour (R = 0.04, p > 0.05;
Spearman R test), oestrogen receptor expression 
(τ = –0.04, p >0.05; Tau Kendall test), progesterone
receptor expression (τ = –0.08, p > 0.05; Tau Kendall
test), HER2 score (τ = 0.1, p > 0.05; Tau Kendall test),
or age of breast carcinoma patients (R = –0.07, 
p > 0.05; Spearman R test).
The intensity of TRAIL expression (intensity of
staining) in breast carcinoma cells did not correlate
with the diameter of the primary tumour (R = 0.03,
p > 0.05; Spearman R test), oestrogen receptor
expression (τ = –0.06, p > 0.05; Tau Kendall test),
progesterone receptor expression (τ  = –0.02, 
p > 0.05; Tau Kendall test), HER2 score (τ = –0.01,
p > 0.05; Tau Kendall test), or age of breast
carcinoma patients (R = 0.06, p > 0.05; Spearman
R test).
The presence of TRAIL expression in breast
carcinoma cells was not statistically associated with
the histological type of breast carcinoma (p = 0.73),
with the presence of lymphovascular invasion 
(p = 0.95), with the presence of metastases in
axillary lymph nodes (p = 0.53) or with infiltration
of the lymph node capsule by lymph node
metastases (p = 0.1) (all tests: two-tailed exact
Fisher’s test or Yates corrected χ2 test).
Similar statistical analysis was also performed
in the subgroup of all 90 ductal invasive breast
carcinomas. The results were similar to those of the
Figure 1. Absence of cytoplasmic TRAIL expression in
breast carcinoma cells. Magnification 200×
Figure 2. Presence of cytoplasmic TRAIL expression in
majority of breast carcinoma cells. Magnification 200× Arch Med Sci 4, August / 2010 549
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whole breast carcinoma group. The percentage of
TRAIL-expressing cells of ductal invasive breast
carcinomas correlated with the nuclear grade 
(τ = 0.32, p < 0.05; Tau Kendall test). Also the
intensity of TRAIL expression (intensity of staining)
in cells of ductal invasive breast carcinomas
correlated with the nuclear grade (τ = 0.19, p < 0.05;
Tau Kendall test). The results of calculations
performed for remaining clinical and pathological
variables were statistically insignificant (p > 0.05).
The statistical analyses of subgroups of other
histological types of breast carcinomas were
abandoned. The number of breast carcinomas in
each of the non-ductal invasive carcinoma
subgroups was too small to achieve reliable
statistical data.   
Discussion
Our analysis revealed that the expression of
TRAIL protein in breast carcinoma cells correlated
with nuclear grade of carcinoma. We found such
a correlation for both the percentage of TRAIL-
expressing cells and for the intensity of TRAIL
staining. To the best of our knowledge, this study
is the first presentation of the correlation of TRAIL
expression with nuclear grade in breast carcinoma
in medical literature. The few authors who have
studied TRAIL expression in breast carcinoma did
not find any correlation with tumour grade [30, 31]. 
In our study, TRAIL expression did not correlate
nor was associated with tumour size, axillary lymph
node status, histological type of carcinoma, or
expression of oestrogen receptor and progesterone
receptor. In this aspect, our observations are similar
to observations made by other authors. Lack of
correlation between TRAIL expression and tumour
size, axillary lymph node status and histological
type of carcinoma was reported by Cross et al. [30].
Lack of correlation between TRAIL and the
expression of oestrogen receptor and progesterone
receptor was reported by Cross et al. [30], by
Sanlioglu et al. [31] and by Van Poznak et al. [32].
In our study we did not find an association between
TRAIL expression and HER2 score. In this aspect our
results are different from the results presented by
Sanlioglu et al. [31], who reported an association
between TRAIL protein and HER2 overexpression in
breast carcinoma. 
In our study we found that TRAIL-expressing
breast carcinomas constitute 73% of all studied
cases. This percentage is higher than the
percentages reported by Herrnring et al. [14] and
Van Poznak et al. [32], who found expression of
TRAIL protein in 52-58% of breast carcinomas. It is
possible that the difference between our results
and the results reported by Herrnring et al. derives
from differences in methodology [14]. Herrnring et
al. did not use the microwave pre-treatment
employed in this study. However, Van Poznak et al.
[32] used a very similar methodology of
immunohistochemical staining to ours; moreover,
our method of evaluation of TRAIL protein
expression was also very similar to the method
used by Van Poznak et al. [32]. Nevertheless, the
difference between the results remains substantial
(Van Poznak et al., 58% vs. our study, 73%). The size
Studied antigens Number of cases Percentage of cases
Expression of oestrogen receptor 
Grade 0 51 43.2
Grade 1+ 18 15.3
Grade 2+ 22 18.6
Grade 3+ 19 16.1
Expression of progesterone receptor 
Grade 0 54 45.8
Grade 1+ 11 9.3
Grade 2+ 24 20.3
Grade 3+ 29 24.6
HER2 receptor score
Score 0 48 40.7
Score 1+ 23 19.5
Score 2+ 27 22.9
Score 3+ 20 16.9
Table II. Results of immunohistochemical stainings for oestrogen, progesterone and HER2 receptors in 118 primary
breast carcinomas550 Arch Med Sci 4, August / 2010
A. Bilski, G. Pasz-Walczak, R. Kubiak, P . Sek, J. Chalubinska, W. Fendler, K. Wronski, A. Piekarska, P . Pluta, P . Potemski, A. Jeziorski, J. Piekarski
of our study group (118 breast carcinomas) is not
small. In fact it is larger than the sizes of groups
analysed by Van Poznak et al. [32] (40 carcinomas),
by Sanlioglu et al. [31] (90 carcinomas) and by
Herrnring et al. [14] (40 carcinomas). All these
authors used classic immunohistochemistry in their
studies, as we did. Therefore, it is tempting to
speculate that we were able to identify a correlation
between grade of breast carcinoma and TRAIL
expression due to the larger number of studied cases.
However, in one very large immuno  histochemical
study performed with the tissue microarray
technique, Cross et al. analysed 395 breast
carcinomas and did not find an association between
grade of breast carcinoma and TRAIL expression [30].
For this reason, we are sure that the cause of the
differences between the studies lies elsewhere. It is
also possible that different methods of grading of
breast carcinomas could be responsible for the
differences in results achieved in the discussed
studies: in our study, the presence of correlations
was assessed with the nuclear grade of cancer; other
authors, such as Sanlioglu et al. [31], used
histopathological grading (Elston-Ellis method [33]). 
In conclusion, our analysis revealed that the
expression of TRAIL protein in breast carcinoma
correlates with a potent unfavourable prognostic
factor – cancer grade. A similar observation was
presented for lung cancer [34]. In melanoma, TRAIL
expression was correlated with high mitotic index
[35]. All these observations indicate generally that
TRAIL protein may be typical for high grade
carcinomas. However, it is still very difficult to define
the role of TRAIL protein in carcinoma cells. There
are two main possibilities. Firstly, TRAIL acts as an
unfavourable factor suppressing cytotoxic activity
of tumour-infiltrating lymphocytes; it helps the
escape of cancer cells from the immune response
[18, 19]. Secondly, TRAIL acts as a favourable factor,
serving as a mechanism of cancer self-regulation;
it inhibits tumour growth by autocrine or paracrine
induction of cancer cell apoptosis [24-26]. 
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